论文部分内容阅读
目的:观察伊曲康唑经验性治疗血液病合并侵袭性真菌感染的疗效和安全性。方法:血液病合并侵袭性真菌感染56例,回顾性分析其基础疾病、临床特点以及应用氟康唑、伊曲康唑进行早期经验性抗真菌治疗的疗效,并就两组间有效率的差异进行统计分析。结果:伊曲康唑治愈率和总有效率分别为36.7%、70%,优于氟康唑,差异有统计学意义。氟康唑治疗无效改用伊曲康唑治疗有效患者影像学改变阳性者占80%。结论:对血液病合并侵袭性真菌感染患者,应用伊曲康唑早期经验性抗真菌治疗有效,安全性高,尤其对存在影像学改变的肺部真菌感染的拟诊患者可以优先。
Objective: To observe the efficacy and safety of itraconazole in the treatment of hematological diseases complicated with invasive fungal infection. Methods: Fifty-six patients with blood-borne and invasive fungal infection were retrospectively analyzed for their underlying diseases, clinical features, and early empirical anti-fungal treatment with fluconazole and itraconazole. The effective rate of the two groups was compared conduct statistical analysis. Results: The cure rate and the total effective rate of itraconazole were 36.7% and 70% respectively, which were better than fluconazole, the difference was statistically significant. Fluconazole treatment ineffective use of itraconazole-treated patients with positive imaging changes accounted for 80%. CONCLUSIONS: Itraconazole-based early anti-fungal therapy is effective and safe for patients with blood-borne and invasive fungal infections. In particular, patients diagnosed with pulmonary fungal infections with imaging changes may be given priority.